Incentivizing physicians to prescribe expensive brand-name chemotherapies instead of generic ones risks burdening patients with high out-of-pocket costs.
Incentivizing physicians to prescribe expensive brand-name chemotherapies instead of generic ones risks burdening patients with high out-of-pocket costs.